123 related articles for article (PubMed ID: 16623055)
1. Advances in alternative pharmacotherapy of ADHD.
Pityaratstian N
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S357-62. PubMed ID: 16623055
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
Popper CW
Child Adolesc Psychiatr Clin N Am; 2000 Jul; 9(3):605-46, viii. PubMed ID: 10944659
[TBL] [Abstract][Full Text] [Related]
3. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
Waxmonsky JG
Essent Psychopharmacol; 2005; 6(5):262-76. PubMed ID: 16222911
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
[TBL] [Abstract][Full Text] [Related]
5. ADHD treatment across the life cycle.
Spencer TJ
J Clin Psychiatry; 2004; 65 Suppl 3():22-6. PubMed ID: 15046532
[TBL] [Abstract][Full Text] [Related]
6. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
7. Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD.
Nair V; Mahadevan S
J Trop Pediatr; 2009 Apr; 55(2):116-21. PubMed ID: 19203986
[TBL] [Abstract][Full Text] [Related]
8. Psychopharmacology of ADHD in adolescents.
Greydanus DE; Sloane MA; Rappley MD
Adolesc Med; 2002 Oct; 13(3):599-624. PubMed ID: 12270803
[TBL] [Abstract][Full Text] [Related]
9. Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
Johnston JA; Ye W; Van Brunt DL; Pohl G; Sumner CR
J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457
[TBL] [Abstract][Full Text] [Related]
10. Non-stimulant treatment of attention-deficit/hyperactivity disorder.
Pliszka SR
CNS Spectr; 2003 Apr; 8(4):253-8. PubMed ID: 12679740
[TBL] [Abstract][Full Text] [Related]
11. Nonstimulant medications for the treatment of ADHD.
Rains A; Scahill L; Hamrin V
J Child Adolesc Psychiatr Nurs; 2006 Feb; 19(1):44-7. PubMed ID: 16464217
[No Abstract] [Full Text] [Related]
12. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Himpel S; Banaschewski T; Heise CA; Rothenberger A
Expert Opin Drug Saf; 2005 Mar; 4(2):311-21. PubMed ID: 15794722
[TBL] [Abstract][Full Text] [Related]
13. Innovations and recent trends in the treatment of ADHD.
Madaan V; Kinnan S; Daughton J; Kratochvil CJ
Expert Rev Neurother; 2006 Sep; 6(9):1375-85. PubMed ID: 17009924
[TBL] [Abstract][Full Text] [Related]
14. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series.
Doyle RL; Frazier J; Spencer TJ; Geller D; Biederman J; Wilens T
J Atten Disord; 2006 Feb; 9(3):543-9. PubMed ID: 16481671
[TBL] [Abstract][Full Text] [Related]
15. New developments in the treatment of ADHD.
Biederman J; Arnsten AF; Faraone SV; Doyle AE; Spencer TJ; Wilens TE; Weiss MD; Safren SA; Culpepper L
J Clin Psychiatry; 2006 Jan; 67(1):148-59. PubMed ID: 16426101
[No Abstract] [Full Text] [Related]
16. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T
Psychiatr Clin North Am; 2004 Jun; 27(2):373-83. PubMed ID: 15064003
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
18. In the pipeline: non-stimulant ADHD meds.
Glazer WM
Behav Healthc; 2010 Jan; 30(1):30-1. PubMed ID: 20184258
[No Abstract] [Full Text] [Related]
19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
20. ADHD through the life span: the role of bupropion in treatment.
Cantwell DP
J Clin Psychiatry; 1998; 59 Suppl 4():92-4. PubMed ID: 9554326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
